|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,942.00 INR | -0.12% |
|
-1.09% | +12.93% |
| 08-05 | CRISIL Keeps AAA Rating on Sun Pharmaceutical's Bank Facilities | MT |
| 07-31 | Sun Pharmaceutical Industries Limited, Q1 2027 Earnings Call, Jul 31, 2026 |
| Market Cap | 4,660B 48.83B 42.29B 39.59B 36.15B 67.99B 69.15B 465B 182B 2,331B 183B 179B 7,779B | P/E 2027 * |
35.8x | P/E 2028 * | 30.3x |
|---|---|---|---|---|---|
| Enterprise Value | 4,380B 45.9B 39.76B 37.22B 33.99B 63.92B 65.01B 437B 171B 2,191B 172B 169B 7,313B | EV / Sales 2027 * |
6.73x | EV / Sales 2028 * | 5.92x |
| Free-Float |
44.39% | Yield 2027 * |
0.88% | Yield 2028 * | 1.02% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.12% | ||
| 1 week | -1.09% | ||
| Current month | -2.44% | ||
| 1 month | +0.34% | ||
| 3 months | +5.09% | ||
| 6 months | +13.71% | ||
| Current year | +12.93% |
| 1 week | 1,925.1 |  | 1,968.2 |
| 1 month | 1,910 | | 2,046.9 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.12% | -1.09% | +22.38% | +68.83% | 48.92B | |
| -1.14% | +9.22% | +60.80% | +124.81% | 41.53B | |
| -0.32% | -0.77% | -1.53% | +16.21% | 12.43B | |
| +6.43% | +6.24% | +27.22% | +81.04% | 11.7B | |
| -0.19% | -0.38% | +30.98% | +137.44% | 9.09B | |
| +1.95% | +9.30% | +24.43% | +40.59% | 7.4B | |
| +1.62% | +3.49% | +41.67% | -13.45% | 7.15B | |
| +1.10% | +2.06% | +12.70% | +180.85% | 6.66B | |
| -1.22% | +7.23% | -25.51% | +28.75% | 5.95B | |
| +0.02% | -0.20% | +34.60% | +100.87% | 4.59B | |
| Average | +0.81% | +3,712.87% | +22.77% | +76.59% | 15.54B | |
| Weighted average by Cap. | +0.27% | +4,978.79% | +30.70% | +83.59% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.82B 5.91B 5.53B 5.05B 9.5B 9.66B 64.9B 25.41B 326B 25.61B 25.05B 1,087B | 729B 7.64B 6.61B 6.19B 5.65B 10.63B 10.81B 72.66B 28.44B 364B 28.67B 28.05B 1,217B |
| Net income | 130B 1.36B 1.18B 1.11B 1.01B 1.9B 1.93B 12.98B 5.08B 65.1B 5.12B 5.01B 217B | 154B 1.62B 1.4B 1.31B 1.2B 2.25B 2.29B 15.37B 6.02B 77.12B 6.07B 5.93B 257B |
| Net Debt | -279B -2.92B -2.53B -2.37B -2.17B -4.07B -4.14B -27.82B -10.89B -140B -10.98B -10.74B -466B | -349B -3.66B -3.17B -2.97B -2.71B -5.1B -5.18B -34.81B -13.63B -175B -13.74B -13.44B -583B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/08/26 | ₹1,942.00 | -0.12% | 2,125,972 |
| 10/08/26 | ₹1,944.40 | -0.03% | 1,726,946 |
| 07/08/26 | ₹1,945.00 | -0.31% | 2,425,268 |
| 06/08/26 | ₹1,951.00 | +0.57% | 1,864,891 |
| 05/08/26 | ₹1,940.00 | -1.22% | 2,152,829 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
